Q2 saw a 6.2% sales decline and lower EBITDA, but cost savings and a stable order book support optimism for H2 recovery. The Selteka acquisition and new facilities are expected to drive growth, while Enedo aims for break-even by year-end.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.